Revolutionizing DBS Therapy for Customized Patient Outcomes and Procedural Efficiencies
Our revolutionary directional lead technology, part of the St. Jude Medical Infinity™ DBS system, places you at the forefront of deep brain stimulation (DBS) therapy, so you can help patients to live their best lives.
Experience precise control
The directional lead for the St. Jude Medical Infinity™ DBS system has segmented electrodes that allow you to precisely steer current towards desired structural areas, helping maximize patient outcomes and reduce side effects.1 It is configured in a single, triple, triple, single band (1-3-3-1) electrode for maximum targeting.
Computational modelling confirms that steering current towards regions of the brain during DBS may help mediate therapeutic effects while potentially avoiding regions of stimulation-induced side-effects.1
The directional lead gives you the ability to provide omnidirectional or targeted stimulation through the use of segmented electrodes. Every electrode can be turned on or off to facilitate stimulation direction, shape and length for precision targeting and adjustment.
Gain procedural efficiencies
Our new technology also features enhanced efficiencies for your practice:
- Programming is easy with an intuitive touch-screen interface.
- The directional lead’s therapeutic current may use less total energy than a radial current field.2
Our directional lead is part of a complete St. Jude Medical Infinity™ DBS system designed to deliver these benefits, as well as enhanced patient comfort and streamlined therapy programming in a wireless iOS‡ software mobile platform.
Contact a St. Jude Medical representative to see how the newest direction in DBS technology can benefit your patients and your practice.
REQUEST MORE INFORMATION
INVESTING IN INNOVATION FOR TODAY AND TOMORROW
The directional lead for the St. Jude Medical Infinity™ DBS system is part of our deep brain stimulation portfolio. Our vision is to transform the management of movement disorders through innovations in symptom control and patient experience and through investments in clinical research. Read more about the portfolio and our approach to movement disorders.